0000000000243315
AUTHOR
Pablo Jimenez
The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
SummarySevere persistent asthma causes a substantial morbidity and mortality burden and is frequently inadequately controlled despite intensive guideline-based therapy. Targeting allergic inflammatory processes that underlie the pathogenesis of severe persistent asthma improves asthma control in a significant proportion of patients. Omalizumab, a humanized monoclonal anti-immunoglobulin E (IgE) antibody, has been developed to target IgE, which is central to triggering and maintaining allergic airway inflammation. In a comprehensive program of clinical trials, omalizumab has been shown to reduce asthma exacerbation and emergency visit rates, and to improve quality of life in patients with se…
Injury prevention in male youth soccer: Current practices and perceptions of practitioners working at elite English academies
Forty-one practitioners inclusive of physiotherapists, sports scientists and strength and conditioning coaches from the academies of elite soccer clubs in the United Kingdom completed an on-line questionnaire which examined their: (1) background information; (2) perceptions of injury occurrence and risk factors; (3) screening and return to play; and (4) approach to designing and delivering injury prevention programmes with a response rate of 55% (41/75). Contact injuries were the most common mechanism reported and players between 13-16 years of age were perceived to be at the greatest risk. Pertinent risk factors included: reduced lower limb and eccentric hamstring strength, proprioception,…
Safety and tolerability of omalizumab
Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…
Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113]
a Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK Mainz University Hospital, 55131 Mainz, Germany Hopital Arnaud de Villeneuve, FR-34000 Montpellier, France Novartis Horsham Research Centre, Horsham, RH12 5AB, UK Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA